Daily Newsletter

08 August 2023

Daily Newsletter

08 August 2023

Ginkgo Bioworks and Merck partner to bolster biologic manufacturing

Ginkgo will receive payments totalling $490m from Merck.

Vishnu Priyan August 08 2023

Ginkgo Bioworks has entered a new partnership with Merck (MSD) to bolster biologic manufacturing.

Ginkgo will offer its cell engineering, protein characterisation, process streamlining and ultra-high-throughput multiplexed screening capabilities to enhance manufacturing efficiency and boost yields for biologics.

The company will receive $490m from MSD.

The sum comprises fees for upfront research and research milestones, as well as payments for option licensing and meeting commercial milestones.

Merck Research Laboratories development sciences and clinical supply senior vice-president Dr Michael Kress stated: “At Merck, we are always seeking new and innovative ways to optimise process efficiency while maintaining product integrity. 

“We are pleased to build upon our relationship with the Ginkgo BioWorks team.”

The parties entered a partnership in October 2022 for a biocatalysis project to streamline MSD's active pharmaceutical ingredient (API) production.

Ginkgo Bioworks CEO and co-founder Jason Kelly stated: “We’re thrilled to leverage our platform to improve the production of biologics in collaboration with Merck. 

“It's exciting for our team to drive impactful and technically innovative work, and to do so shoulder-to-shoulder with our counterparts at Merck.”

In May 2023, Ginkgo Bioworks partnered with Boehringer Ingelheim for the development of breakthrough therapies for conditions that are difficult to treat.

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close